AU2015311730A1 - Camkii inhibitors and uses thereof - Google Patents

Camkii inhibitors and uses thereof Download PDF

Info

Publication number
AU2015311730A1
AU2015311730A1 AU2015311730A AU2015311730A AU2015311730A1 AU 2015311730 A1 AU2015311730 A1 AU 2015311730A1 AU 2015311730 A AU2015311730 A AU 2015311730A AU 2015311730 A AU2015311730 A AU 2015311730A AU 2015311730 A1 AU2015311730 A1 AU 2015311730A1
Authority
AU
Australia
Prior art keywords
hydrogen
optionally substituted
group
independently selected
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015311730A
Other languages
English (en)
Other versions
AU2015311730A8 (en
Inventor
Chundru BALASUBRAMANYAM
Brahmaiah DABBUGODDU
Nangunoori Sampath KUMAR
Daniel E. Levy
Bheema Rao Paraselli
Howard Schulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allosteros Therapeutics Inc
Original Assignee
ALLOSTEROS THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALLOSTEROS THERAPEUTICS Inc filed Critical ALLOSTEROS THERAPEUTICS Inc
Publication of AU2015311730A1 publication Critical patent/AU2015311730A1/en
Publication of AU2015311730A8 publication Critical patent/AU2015311730A8/en
Priority to AU2020203927A priority Critical patent/AU2020203927B9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2015311730A 2014-09-05 2015-09-04 Camkii inhibitors and uses thereof Abandoned AU2015311730A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203927A AU2020203927B9 (en) 2014-09-05 2020-06-12 CaMKII inhibitors and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046450P 2014-09-05 2014-09-05
US62/046,450 2014-09-05
PCT/US2015/048640 WO2016037106A1 (en) 2014-09-05 2015-09-04 CaMKII INHIBITORS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203927A Division AU2020203927B9 (en) 2014-09-05 2020-06-12 CaMKII inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
AU2015311730A1 true AU2015311730A1 (en) 2017-04-20
AU2015311730A8 AU2015311730A8 (en) 2017-05-11

Family

ID=54150675

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015311730A Abandoned AU2015311730A1 (en) 2014-09-05 2015-09-04 Camkii inhibitors and uses thereof
AU2020203927A Active AU2020203927B9 (en) 2014-09-05 2020-06-12 CaMKII inhibitors and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203927A Active AU2020203927B9 (en) 2014-09-05 2020-06-12 CaMKII inhibitors and uses thereof

Country Status (7)

Country Link
US (2) US10759792B2 (ja)
EP (1) EP3189052B1 (ja)
JP (2) JP6782227B2 (ja)
CN (1) CN107074856A (ja)
AU (2) AU2015311730A1 (ja)
CA (1) CA2960101A1 (ja)
WO (1) WO2016037106A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
WO2019049148A1 (en) * 2017-09-10 2019-03-14 Carmel Haifa University Economic Corporation Ltd. METHOD OF TREATING DEPRESSION AND MAJOR DEPRESSIVE DISORDER
CN108218862B (zh) * 2018-02-07 2020-06-23 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
EP3755800A1 (en) 2018-02-21 2020-12-30 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
CN108904532B (zh) * 2018-08-20 2021-07-27 上海市第一人民医院 一种富勒烯C60纳米晶体联合CaMKII抑制剂的组合物的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1913124A (en) * 1932-01-02 1933-06-06 American Sundries Co Inc Vaporizer
US2690441A (en) * 1953-06-11 1954-09-28 Searle & Co 3-carboline derivatives
GB1268773A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
BE758991A (fr) * 1969-11-18 1971-05-17 Reeves Bros Inc Procede de reticulation hydrodynamique d'une mousse de polyurethanne
PL80610B1 (ja) * 1970-03-12 1975-08-30
GB8600651D0 (en) * 1986-01-11 1986-02-19 Beecham Group Plc Compounds
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
JP2001509808A (ja) 1997-01-31 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
NZ532327A (en) 2001-10-01 2005-10-28 Univ Vanderbilt Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
WO2004058764A1 (en) 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
WO2006007422A2 (en) 2004-06-16 2006-01-19 The Trustees Fo Columbia University In The City Of New York CaMKII/CALCIUM CHANNEL PHOSPHORYLATION-RELATED COMPOSITIONS AND METHODS
FR2876377B1 (fr) * 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
CN101052420A (zh) 2004-11-02 2007-10-10 大日本住友制药株式会社 用于治疗自体免疫疾病的并用药
US20080300267A1 (en) 2005-05-16 2008-12-04 Barun Okram Compounds and Compositions as Protein Kinase Inhibitors
EP1881983B1 (en) 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridines useful as inhibitors of protein kinase
US20070004684A1 (en) * 2005-06-09 2007-01-04 Boehringer Ingelheim International Gmbh Alpha-Carbolines as CDK-1 inhibitors
WO2007005831A2 (en) 2005-07-01 2007-01-11 Texas A & M University System Zinc oxide polymer nanocomposites and methods of producing zinc oxide polymer nanocomposites
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
PL2247558T3 (pl) * 2008-02-14 2022-05-02 Eli Lilly And Company Nowe środki obrazujące do wykrywania czynnościowych zaburzeń neurologicznych
MX2011000837A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa triciclica.
EP2323482A4 (en) 2008-08-06 2011-08-17 Merck & Co Inc SUBSTITUTED DIHYDROISOCHINOLINONE AND ISOCHINOLINDION DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
EP2161271A1 (en) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
BRPI0919948A2 (pt) 2008-10-31 2015-08-25 Madivation Technologies Inc Pirido[4,3-b]indois contendo porções rígidas
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
US8440656B2 (en) 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP3330269B1 (en) 2011-09-19 2023-06-07 Kumar, Ajay Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
EA030253B1 (ru) * 2012-09-28 2018-07-31 Кэнсэр Ресерч Текнолоджи Лимитед Азахиназолиновые ингибиторы атипичной протеинкиназы c
WO2014138212A1 (en) 2013-03-06 2014-09-12 Allosteros Therapeutics, Inc. CaMKII INHIBITORS AND USES THEREOF

Also Published As

Publication number Publication date
US10759792B2 (en) 2020-09-01
US20200385383A1 (en) 2020-12-10
EP3189052A1 (en) 2017-07-12
CA2960101A1 (en) 2016-03-10
JP2017534572A (ja) 2017-11-24
AU2015311730A8 (en) 2017-05-11
AU2020203927B2 (en) 2021-06-24
AU2020203927B9 (en) 2021-07-08
JP6782227B2 (ja) 2020-11-11
WO2016037106A1 (en) 2016-03-10
JP6918378B2 (ja) 2021-08-11
US11325908B2 (en) 2022-05-10
JP2020143161A (ja) 2020-09-10
CN107074856A (zh) 2017-08-18
US20170247374A1 (en) 2017-08-31
AU2020203927A1 (en) 2020-07-02
EP3189052B1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
US11325908B2 (en) CaMKII inhibitors and uses thereof
KR102622161B1 (ko) 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법
US11555026B2 (en) AHR inhibitors and uses thereof
EP2903613B1 (en) Pyrazole derivatives useful as inhibitors of irak4 activity
AU2014225889B2 (en) CaMKII inhibitors and uses thereof
JP7067725B2 (ja) Ａｃｃ阻害剤としての新規な化合物およびそれらの使用
AU2013334102A1 (en) Modulators of resistant androgen receptor
CA2837268A1 (en) Compositions and methods for modulating a kinase
US20190144437A1 (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
WO2020102616A1 (en) Acly inhibitors and uses thereof
AU2012312302A1 (en) Compounds useful as inhibitors of choline kinase
EA042939B1 (ru) Ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 15 , PAGE(S) 2269 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ALLOSTEROS THERAPEUTICS, INC, APPLICATION NO. 2015311730, UNDER INID (54) CORRECT THE TITLE TO READ CAMKII INHIBITORS AND USES THEREOF

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted